158 related articles for article (PubMed ID: 22964253)
1. Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing.
Cattaneo D; Baldelli S; Cerea M; Landonio S; Meraviglia P; Simioni E; Cozzi V; Fucile S; Gazzaniga A; Clementi E; Galli M; Rizzardini G; Gervasoni C
Antimicrob Agents Chemother; 2012 Dec; 56(12):6132-6. PubMed ID: 22964253
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label, 2-period, single-dose, crossover phase 1 study.
Cattaneo D; Cossu MV; Fucile S; Riva A; Baldelli S; Meraviglia P; Landonio S; Impagnatiello C; Resnati C; Galli M; Clementi E; Capetti A; Rizzardini G; Gervasoni C
Ther Drug Monit; 2015 Feb; 37(1):119-25. PubMed ID: 24988438
[TBL] [Abstract][Full Text] [Related]
3. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.
Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Conti F; Clementi E
Ther Drug Monit; 2010 Dec; 32(6):782-6. PubMed ID: 20926993
[TBL] [Abstract][Full Text] [Related]
4. Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting.
Siccardi M; DʼAvolio A; Rodriguez-Novoa S; Cuenca L; Simiele M; Baietto L; Calcagno A; Moss D; Bonora S; Soriano V; Back DJ; Owen A; Di Perri G
Ther Drug Monit; 2012 Apr; 34(2):232-5. PubMed ID: 22406652
[TBL] [Abstract][Full Text] [Related]
5. Determination of raltegravir and raltegravir glucuronide in human plasma and urine by LC-MS/MS with application in a maternal-fetal pharmacokinetic study.
Moreira FL; Marques MP; Duarte G; Lanchote VL
J Pharm Biomed Anal; 2020 Jan; 177():112838. PubMed ID: 31525573
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy.
Ananworanich J; Gorowara M; Avihingsanon A; Kerr SJ; van Heesch N; Khongpetch C; Uanithirat A; Hill A; Ruxrungtham K; Burger DM;
Antimicrob Agents Chemother; 2012 Apr; 56(4):1892-8. PubMed ID: 22252825
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study.
Barau C; Braun J; Vincent C; Haim-Boukobza S; Molina JM; Miailhes P; Fournier I; Aboulker JP; Vittecoq D; Duclos-Vallée JC; Taburet AM; Teicher E;
Clin Infect Dis; 2014 Oct; 59(8):1177-84. PubMed ID: 24992955
[TBL] [Abstract][Full Text] [Related]
8. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure.
Patterson KB; Prince HA; Stevens T; Shaheen NJ; Dellon ES; Madanick RD; Jennings S; Cohen MS; Kashuba AD
AIDS; 2013 Jun; 27(9):1413-9. PubMed ID: 23945503
[TBL] [Abstract][Full Text] [Related]
9. Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.
Do VT; Higginson RT; Fulco PP
Am J Health Syst Pharm; 2011 Nov; 68(21):2049-54. PubMed ID: 22011983
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.
Nachman S; Alvero C; Teppler H; Homony B; Rodgers AJ; Graham BL; Fenton T; Frenkel LM; Browning RS; Hazra R; Wiznia AA;
Lancet HIV; 2018 Dec; 5(12):e715-e722. PubMed ID: 30527329
[TBL] [Abstract][Full Text] [Related]
11. A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults.
Carey D; Pett SL; Bloch M; Wand H; MacRae K; Beileiter K; Ray JE; Boyd MA; Emery S; Cooper DA
J Acquir Immune Defic Syndr; 2012 Jun; 60(2):143-9. PubMed ID: 22421745
[TBL] [Abstract][Full Text] [Related]
12. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.
Eron JJ; Rockstroh JK; Reynes J; Andrade-Villanueva J; Ramalho-Madruga JV; Bekker LG; Young B; Katlama C; Gatell-Artigas JM; Arribas JR; Nelson M; Campbell H; Zhao J; Rodgers AJ; Rizk ML; Wenning L; Miller MD; Hazuda D; DiNubile MJ; Leavitt R; Isaacs R; Robertson MN; Sklar P; Nguyen BY;
Lancet Infect Dis; 2011 Dec; 11(12):907-15. PubMed ID: 21933752
[TBL] [Abstract][Full Text] [Related]
13. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
14. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.
Goethals O; Van Ginderen M; Vos A; Cummings MD; Van Der Borght K; Van Wesenbeeck L; Feyaerts M; Verheyen A; Smits V; Van Loock M; Hertogs K; Schols D; Clayton RF
Antiviral Res; 2011 Aug; 91(2):167-76. PubMed ID: 21669228
[TBL] [Abstract][Full Text] [Related]
15. Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110).
Clarke DF; Acosta EP; Cababasay M; Wang J; Chain A; Teppler H; Popson S; Graham B; Smith B; Hazra R; Calabrese K; Bryson Y; Spector SA; Lommerse J; Mirochnick M;
J Acquir Immune Defic Syndr; 2020 May; 84(1):70-77. PubMed ID: 31913995
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
Gantner P; Koeppel C; Partisani M; Batard ML; Bernard-Henry C; Cheneau C; De Mautort E; Priester M; Muret P; Sueur C; Fafi-Kremer S; Rey D
Scand J Infect Dis; 2014 Dec; 46(12):838-45. PubMed ID: 25229167
[TBL] [Abstract][Full Text] [Related]
17. Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection.
Sandkovsky U; Swindells S; Moore R; Acosta EP; Fletcher CV
Pharmacotherapy; 2012 Feb; 32(2):142-7. PubMed ID: 22392423
[TBL] [Abstract][Full Text] [Related]
18. Raltegravir: the first HIV integrase inhibitor.
Cocohoba J; Dong BJ
Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
[TBL] [Abstract][Full Text] [Related]
19. Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects.
Cattaneo D; Gervasoni C; Meraviglia P; Landonio S; Fucile S; Cozzi V; Baldelli S; Pellegrini M; Galli M; Clementi E
J Antimicrob Chemother; 2012 Feb; 67(2):460-4. PubMed ID: 22127581
[TBL] [Abstract][Full Text] [Related]
20. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.
de Kanter CT; Blonk MI; Colbers AP; Schouwenberg BJ; Burger DM
Clin Infect Dis; 2013 Jan; 56(2):300-6. PubMed ID: 23001704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
